secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0000950170-23-051917
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma and Vaxcyte finalize agreement triggering $5M payment; license amended
--------------------------------------------------------------------------------

- Vaxcyte agrees to pay Sutro $5.0M upon mutual agreement on Form Definitive Agreement, reached Sept 28, 2023.
- Amendment No. 3 modifies royalty reduction provisions, IP ownership, prosecution, and financial reporting terms.
- Vaxcyte gains rights to independently source cell-free extract from CMOs and option to internally manufacture extract.
- Amendment effective immediately; negotiated under December 2022 letter agreement between the companies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023051917/0000950170-23-051917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023051917/stro-20230928.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-051917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer